Imexpharm Corporation (HOSE:IMP)

Imexpharm Income Statement

Financials in millions VND. Fiscal year is January - December.

Fiscal Year	TTM	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020
Period Ending	Jun 30, 2025	Dec 31, 2024	Jan 1, 2024	Dec 31, 2022	Dec 31, 2021	Dec 31, 2020
Revenue	2,423,552	2,205,120	1,994,037	1,643,707	1,266,597	1,369,422
Revenue Growth (YoY)	16.33%	10.59%	21.31%	29.77%	-7.51%	-2.35%
Cost of Revenue	1,280,942	1,181,634	1,010,064	824,152	669,657	750,104
Gross Profit	1,142,610	1,023,486	983,973	819,555	596,940	619,318
Selling, General & Admin	679,611	608,328	602,926	523,055	362,868	356,763
Operating Expenses	679,611	608,328	602,926	523,055	362,868	356,763
Operating Income	462,999	415,158	381,047	296,500	234,072	262,555
Interest Expense	-10,613	-3,489	-6,036	-3,795	-5,496	-5,408
Interest & Investment Income	17,270	7,929	19,877	19,853	12,364	7,015
Currency Exchange Gain (Loss)	2,024	2,410	2,613	-2,053	3,436	1,882
Other Non Operating Income (Expenses)	-20,843	-19,555	-20,221	-19,448	-9,413	-10,173
EBT Excluding Unusual Items	450,837	402,453	377,279	291,059	234,963	255,870
Gain (Loss) on Sale of Investments	1,741	1,740	-6.02	345.28	3,896	-429.04
Gain (Loss) on Sale of Assets	923.95	-	-	-	-	-
Pretax Income	453,502	404,193	377,273	291,404	238,859	255,441
Income Tax Expense	95,727	83,331	77,717	67,864	49,764	45,744
Net Income	357,775	320,862	299,556	223,540	189,095	209,697
Preferred Dividends & Other Adjustments	28,495	23,327	21,778	39,697	15,582	30,039
Net Income to Common	329,281	297,536	277,778	183,844	173,513	179,658
Net Income Growth	32.56%	7.11%	34.01%	18.22%	-9.83%	29.13%
Shares Outstanding (Basic)	154	154	154	154	154	150
Shares Outstanding (Diluted)	154	154	154	154	154	150
Shares Change (YoY)	-1.90%	-	-0.00%	-0.00%	2.92%	0.86%
EPS (Basic)	2138.06	1931.94	1803.65	1193.71	1126.63	1200.54
EPS (Diluted)	2138.06	1931.94	1803.65	1193.64	1126.63	1200.43
EPS Growth	36.04%	7.11%	51.11%	5.95%	-6.15%	24.64%
Free Cash Flow	24,207	119,497	-103,064	279,250	182,024	-16,531
Free Cash Flow Per Share	157.18	775.91	-669.21	1813.19	1181.89	-110.47
Dividend Per Share	500.000	500.000	454.546	432.901	649.351	649.351
Dividend Growth	10.00%	10.00%	5.00%	-33.33%	-	95.00%
Gross Margin	47.15%	46.41%	49.35%	49.86%	47.13%	45.23%
Operating Margin	19.10%	18.83%	19.11%	18.04%	18.48%	19.17%
Profit Margin	13.59%	13.49%	13.93%	11.19%	13.70%	13.12%
Free Cash Flow Margin	1.00%	5.42%	-5.17%	16.99%	14.37%	-1.21%
EBITDA	565,833	519,393	463,689	356,886	294,484	315,916
EBITDA Margin	23.35%	23.55%	23.25%	21.71%	23.25%	23.07%
D&A For EBITDA	102,834	104,235	82,642	60,386	60,412	53,361
EBIT	462,999	415,158	381,047	296,500	234,072	262,555
EBIT Margin	19.10%	18.83%	19.11%	18.04%	18.48%	19.17%
Effective Tax Rate	21.11%	20.62%	20.60%	23.29%	20.83%	17.91%
Revenue as Reported	2,423,552	2,205,120	1,994,037	1,643,707	1,266,597	1,369,422
Advertising Expenses	-	170,332	175,099	123,665	110,468	74,360

Updated Jan 20, 2025. Source: S&P Global Market Intelligence. Standard template. Financial Sources.